JP2019535754A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535754A5
JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
Authority
JP
Japan
Prior art keywords
formula
compound according
compound
pharmaceutically acceptable
equation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019527426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535754A (ja
JP7167021B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/063182 external-priority patent/WO2018098390A1/en
Publication of JP2019535754A publication Critical patent/JP2019535754A/ja
Publication of JP2019535754A5 publication Critical patent/JP2019535754A5/ja
Application granted granted Critical
Publication of JP7167021B2 publication Critical patent/JP7167021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019527426A 2016-11-23 2017-11-24 アルブミン結合psma阻害剤 Active JP7167021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (3)

Publication Number Publication Date
JP2019535754A JP2019535754A (ja) 2019-12-12
JP2019535754A5 true JP2019535754A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7167021B2 JP7167021B2 (ja) 2022-11-08

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527426A Active JP7167021B2 (ja) 2016-11-23 2017-11-24 アルブミン結合psma阻害剤

Country Status (8)

Country Link
US (1) US11147889B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544960A1 (cg-RX-API-DMAC7.html)
JP (1) JP7167021B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982998A (cg-RX-API-DMAC7.html)
BR (1) BR112019010206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043619A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019005742A (cg-RX-API-DMAC7.html)
WO (1) WO2018098390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
WO2020102348A1 (en) 2018-11-14 2020-05-22 Stephen Dimagno Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
AU2020257786B2 (en) 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
BR112021025810A2 (pt) 2019-06-21 2022-05-10 Provincial Health Services Authority Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
AU2021230210A1 (en) 2020-03-04 2022-09-22 Kyoto University Compound and radioactive labeling compound
AU2021267477A1 (en) * 2020-05-06 2022-12-01 Cornell University Copper-containing theragnostic compounds and methods of use
AU2021390552A1 (en) * 2020-12-04 2023-06-29 The Regents Of The University Of California Peptide receptor radionuclide therapy
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
AU2022228911A1 (en) 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
EP3066105A4 (en) * 2013-11-06 2017-10-11 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
EP3533473A3 (en) * 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원(psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
RS65188B1 (sr) * 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
CN109843339B (zh) * 2016-06-23 2023-07-07 康奈尔大学 影响肿瘤杀伤的双重靶向构建体
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Similar Documents

Publication Publication Date Title
JP2019535754A5 (cg-RX-API-DMAC7.html)
CN101668547B (zh) 选择缺氧组织的弱碱性2-硝基咪唑递送剂及其应用方法
US8435489B2 (en) Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US11147889B2 (en) Albumin-binding PSMA inhibitors
US11541133B2 (en) Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
JP2014510729A5 (cg-RX-API-DMAC7.html)
JP2006501149A5 (cg-RX-API-DMAC7.html)
JP2006524250A5 (cg-RX-API-DMAC7.html)
JP2010523599A5 (cg-RX-API-DMAC7.html)
WO2008124651A3 (en) Nitro-imidazole hypoxia imaging agents
JP2010511704A5 (cg-RX-API-DMAC7.html)
CA3030907A1 (en) Chelated psma inhibitors
DE602004017290D1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
JP2015528814A5 (cg-RX-API-DMAC7.html)
JP2016528299A5 (cg-RX-API-DMAC7.html)
JP2012504131A5 (cg-RX-API-DMAC7.html)
CA2722858C (en) Substrate based pet imaging agents
CN111447955A (zh) 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途
JP2013504590A5 (cg-RX-API-DMAC7.html)
JP2018502150A5 (cg-RX-API-DMAC7.html)
JP2009538894A5 (cg-RX-API-DMAC7.html)
Subbarayan et al. Evaluation studies of technetium-99m-porphyrin (T3, 4BCPP) for tumor imaging
Welch et al. Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides
JP2024542261A (ja) 診療に寄与する新規ホウ素リポソーム
JP6263716B2 (ja) 悪性腫瘍のpet診断用トレーサー